| Similar Articles |
|---|
 |
Chemistry World
July 8, 2015
Phillip Broadwith |
Thermo Fisher to buy Alfa Aesar chemical supplies The acquisition complements its existing Fisher Scientific chemicals supply segment, and will be integrated with its laboratory products and services portfolio.   |
Bio-IT World
April 2006
John Russell |
Lobbying for Critical Path Funding The FDA's Critical Path Initiative is an important program in need of cold hard cash and dedicated FDA personnel. |
The Motley Fool
October 26, 2007
Brian Orelli |
This Just In: Mergers Do Indeed Lower Costs As the anniversary integration between Thermo Electron and Fisher Scientific approaches next week, Thermo Fisher Scientific announced third-quarter results that demonstrated how the integration is having a nice effect on the bottom line. |
Pharmaceutical Executive
May 1, 2006
Jill Wechsler |
Washington Report: Opportunity Knocks FDA has finally released its long-awaited list of research opportunities for the Critical Path initiative. Now comes the hard part, as companies learn how to collaborate on projects that will benefit pharma as a whole. |
The Motley Fool
February 7, 2008
Brian Orelli |
A Lab Match Made in Heaven The case of Thermo Electron and Fisher Scientific shows why mergers work. |
Chemistry World
May 10, 2006
Katharine Sanderson |
Leading Lab Suppliers Merge Analytical instrument firm Thermo Electron and chemical manufacturer Fisher Scientific announced a merger, aiming to become the leading provider of laboratory products and services in the health sciences industry. |
Pharmaceutical Executive
May 1, 2007
Weiner & Hovde |
Critical Mass for Critical Path? Everyone agrees that it's the road to pharma's future, but no one's rushing to take it. Yet with growing FDA advocacy and new advances in biomarkers and drug-disease modeling, the rewards of collaboration now look greater than the risks. |
Bio-IT World
August 2005
Johan Bostrom |
Agilent Acquisitions Bolster Portfolio of Products A string of acquisitions is helping Agilent Technologies establish itself as a major player in informatics for analytical laboratories, and its expanding product portfolio has made it a serious player in laboratory analysis automation and software integration. |
Pharmaceutical Executive
January 1, 2006
Clinton & Wechsler |
What Ever Happened to Critical Path FDA's ambitious program to improve drug development disappeared from view almost as soon as it was announced. Suddenly, it's back, but is it here to stay? |
Pharmaceutical Executive
September 1, 2005
Mattingly & Saxberg |
Biomarkers Come of Age In the past five years, biomarkers have become an essential part of pharmaceutical R&D. Seven industry experts explain how it happened - and what comes next. |
The Motley Fool
May 8, 2006
Stephen D. Simpson |
Fisher Scientific Reels In a Deal A fair price and impressive market leverage give this merger between Fisher Scientific and Thermo Electron a better-than-average chance. Shareholders, take note. |
Bio-IT World
February 2007
Mike May |
No Limits: The New Look of LIMS As vendors and scientists work towards standardized data formats and improving the tracking of research and results worldwide, laboratory information management systems can pull increasingly more complex sources of information into managing knowledge. |
The Motley Fool
November 9, 2005
Stephen D. Simpson |
Fishing for Value at Fisher Even with today's earnings-induced jump, there still might be some value here at researcher Fisher Scientific. Investors, take note. |
CIO
July 27, 2012
Kim S. Nash |
How Thermo Fisher Mines Customer Feedback to Improve Service Thermo Fisher Scientific overhauled its customer feedback system to allow it to be more responsive to current customers and to take advantage of emerging markets |
Bio-IT World
Dec 2006/Jan 2007 |
Resolute in the New Year Industry leaders in areas from pharmacogenetics to cheminformatics found 2006 to be a year of important steps forward, but looked with even more anticipation to 2007: Allen D. Roses, SVP, Pharmacogenetics GlaxoSmithKline... etc. |
Salon.com
May 1, 2000
Arthur Allen |
Listening to DNA The genome project is getting the buzz. But the real breakthroughs may come from labs out of the limelight, like Gene Logic. |
Bio-IT World
Jul/Aug 2006
Eric K. Neumann |
Combining Drug Toxicity Knowledge Nearly half the drugs entering clinical trials will fail because of some form of serious toxicity that was missed in preclinical studies. These failures should not happen at such a late stage in the process. So what can be done? |
Bio-IT World
April 2007
Malorye Allison |
Biomarkers versus Blockbusters Are companies really changing their strategies and using biomarkers to target smaller, better defined patient sets with their new drugs? Or is the vast majority of pharma biomarker studies just aimed at culling bad drugs from their pipelines? |
Chemistry World
January 8, 2014
Phillip Broadwith |
Thermo Fisher to sell three analytical divisions to GE Healthcare GE will take over Thermo's cell culture supplies, gene modulation and magnetic beads businesses, which are expected to generate combined sales in the region of $250 million for 2013. |
Bio-IT World
March 8, 2005
Patricia Reilly |
Biomarkers: Trends and Potential Companies are centralizing biomarker research to help reduce spending. |
Bio-IT World
July 2005
Robert M. Frederickson |
Amassing Mass Spectrometry Tools Mass spectrometry is a key tool in the effort to identify protein biomarkers of human disease. Manufacturers have met major challenges in adapting this technology to protein discovery, both qualitatively and quantitatively. |
Bio-IT World
August 18, 2004 |
Project Summaries Drug Discovery and Development: Ace BioSciences... Compugen... Entelos/Organon... Iconix Pharmaceuticals... Johnson & Johnson Pharmaceutical Research & Development... Laboratoire Kastler Brossel ... etc. |
The Motley Fool
August 16, 2007
Brian Orelli |
More Drugmaker Growth Without the FDA All that high-tech lab equipment has to come from somewhere. Here's how investors can benefit from it, too. |
Bio-IT World
June 17, 2004
Michael A. Greeley |
A Bet on Biomarkers Biomarkers are a hot topic among venture capitalists these days and while they are becoming increasingly important in drug discovery and delivery processes, there is great debate about the best business models for marketing the related tools. |
Chemistry World
July 2010
Anna Lewcock |
Medicine made to measure Healthcare tailored to suit the genetic makeup of the patient is finally coming to fruition. |
Chemistry World
April 19, 2013
Sarah Houlton |
Thermo Fisher to buy Life Technologies in $15.8bn deal Life Technologies specializes in research products, with a particular focus on genetic sequencing and DNA analysis. |
The Motley Fool
October 26, 2011
Tim Beyers |
Thermo Fisher Scientific Shares Plunged: What You Need to Know Shares of Thermo Fisher Scientific fell more than 10% in early trading and closed off almost that much after lowering full-year earnings and revenue guidance. |
